July 24th 2024
The PDUFA goal date for TLX007-CDx is March 24, 2025.
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Dr. Ravi on the increased burden of the 177Lu-PSMA-617 shortage for newly referred patients
March 29th 2023"Where it's feasible and where the patients are eligible, I and others are trying to use alternative therapies, which have probably a similar impact in terms of improving longevity of life for patients [with prostate cancer]," says Praful Ravi, MD, BChir, MRCP.
How the ongoing shortage of 177Lu-PSMA-617 in the US affects care for patients with prostate cancer
March 28th 2023"Some of these patients newly referred don't have any other proven therapies remaining...This is the only one on the shelf that has a proven benefit. Unfortunately, we can't offer them that at this stage," says Praful Ravi, MD, BChir, MRCP.
Trial of 64Cu SAR-bisPSMA in biochemically recurrent prostate cancer hits enrollment goal
February 9th 2023"We are very pleased to have reached our recruitment target for the COBRA trial. The data generated thus far on the SAR-bisPSMA product is very encouraging and shows high uptake of the agent by prostate cancer cells,” said Neal Shore, MD.
Insight for practicing clinicians on targeted radionuclide therapies for prostate cancer
December 12th 2022“In terms of both numbers of centers [administering radionuclides] as well as the amount of drug that’s available, [both] are going to increase over the next several months and certainly, year,” says Scott T. Tagawa, MD, MS, FACP.
Dr. Tagawa on pivotal trials supporting use of 177Lu-PSMA-617 in prostate cancer
December 8th 2022177Lu-PSMA-617 is approved for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting.
177Lu-PSMA-617 significantly improves rPFS in earlier mCRPC setting
December 6th 2022According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting.